Aaron Kantoff
CIK: 0001862734
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (10 total)
- Jun 2, 2026AVTX
Avalo Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
20.1K shares- - Oct 28, 2025TRML
Tourmaline Bio, Inc.
Tender Offer(U)Direct88.3K shares- - Oct 28, 2025TRML
Tourmaline Bio, Inc.
Disposition(D)DirectEmployee Stock Option (Right to Buy)
16.8K shares- - Oct 28, 2025TRML
Tourmaline Bio, Inc.
Disposition(D)DirectEmployee Stock Option (Right to Buy)
10K shares- - Oct 24, 2025TRML
Tourmaline Bio, Inc.
Gift(G)Direct5K shares- - Sep 5, 2025TRML
Tourmaline Bio, Inc.
Exercise(M)Direct10K shares at avg. $9.46$95K - Sep 5, 2025TRML
Tourmaline Bio, Inc.
Exercise(M)Direct37.9K shares at avg. $0.13$5K - Jun 17, 2025AVTX
Avalo Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
20.1K shares- - Jun 4, 2025TRML
Tourmaline Bio, Inc.
Award(A)DirectStock Option (Right to Buy)
16.8K shares- - Mar 28, 2025AVTX
Avalo Therapeutics, Inc.
Exercise(M)Direct3.2K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 2, 2026 |  AVTX Avalo Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 20,100 | - | - | Direct |
| Oct 28, 2025 |  TRML Tourmaline Bio, Inc. | Tender Offer(U) | 88,281 | - | - | Direct |
| Oct 28, 2025 | TRML Tourmaline Bio, Inc. | Disposition(D) Employee Stock Option (Right to Buy) | 16,800 | - | - | Direct |
| Oct 28, 2025 | TRML Tourmaline Bio, Inc. | Disposition(D) Employee Stock Option (Right to Buy) | 10,000 | - | - | Direct |
| Oct 24, 2025 | TRML Tourmaline Bio, Inc. | Gift(G) | 5,000 | - | - | Direct |
| Sep 5, 2025 | TRML Tourmaline Bio, Inc. | Exercise(M) | 10,000 | $9.46 | $94,600 | Direct |
| Sep 5, 2025 | TRML Tourmaline Bio, Inc. | Exercise(M) | 37,890 | $0.13 | $4,926 | Direct |
| Jun 17, 2025 | AVTX Avalo Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 20,100 | - | - | Direct |
| Jun 4, 2025 | TRML Tourmaline Bio, Inc. | Award(A) Stock Option (Right to Buy) | 16,800 | - | - | Direct |
| Mar 28, 2025 | AVTX Avalo Therapeutics, Inc. | Exercise(M) | 3,167 | - | - | Direct |
1-10 of 10 transactions
About KANTOFF AARON
KANTOFF AARON (SEC CIK 0001862734) files insider reports with the SEC as Director of Avalo Therapeutics, Inc. (AVTX) and Director of Tourmaline Bio, Inc. (TRML).
Signal8 holds 7 ownership filings by KANTOFF AARON, all Form 4s, filed between Apr 1, 2025 and Jun 4, 2026. Those filings report 10 transactions, from Mar 28, 2025 to Jun 2, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on KANTOFF AARON's filings is in WAYNE, PA.
Recent filings by KANTOFF AARON
- Jun 2, 2026: Grant or award of AVTX derivative securities (Form 4, code A).
- Oct 28, 2025: Tender of shares transaction of TRML shares (Form 4, code U).
- Oct 28, 2025: Disposition to issuer transactions of TRML derivative securities (2 lines, Form 4, code D).
- Oct 24, 2025: Gift of TRML shares (Form 4, code G).
- Sep 5, 2025: Option exercises of TRML shares (2 lines, Form 4, code M).
Other insiders filing for Avalo Therapeutics, Inc. (AVTX)
- Jain Rita, Director
- Lind Kevin Robert, Director
- Philip Ron M, Director
- Sullivan Christopher Ryan, Chief Financial Officer
- Doyle Mittie, Chief Medical Officer
- Riley Jennifer, Chief Strategy Officer